Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...
Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
HutanBio, a Malaysian spin-out from scientists at Cambridge University, UK, has bagged a first tranche of seed investment from London-based Clean...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Roche leads Freenome Inc US$257m financing
Roche led the financing that will be used by San Francisco-based Freenome Inc to finance testing its early cancer detection platform in the Vallania...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...